Advertisement

International Journal of Colorectal Disease

, Volume 22, Issue 6, pp 651–659 | Cite as

Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1, -8 and -12

  • J. Gröne
  • B. Weber
  • E. Staub
  • M. Heinze
  • I. Klaman
  • C. Pilarsky
  • K. Hermann
  • E. Castanos-Velez
  • S. Röpcke
  • B. Mann
  • A. Rosenthal
  • H. J. Buhr
Original Article

Abstract

Background and aims

As integral membrane proteins, claudins form tight junctions together with occludin. Several claudins were shown to be up-regulated in various cancer types. We performed an expression analysis of genes encoding tight junction proteins to display differential gene expression on RNA and protein level and to identify and validate potential targets for colorectal cancer (CRC) therapy.

Patients and methods

Amplified and biotinylated cRNA from 30 microdissected CRC specimen and corresponding normal tissues was hybridized to Affymetrix U133set GeneChips. Quantification of differential protein expression of claudin-1, -8 and -12 between normal and corresponding tumour tissues was performed by Western blot analyses. Paraffin-embedded CRC tissue samples, colon cancer cell lines and normal tissue microarray were analysed for protein expression of claudin-1 by immunohistochemistry (IHC).

Results

Claudin-1 (CLDN1) and -12 (CLDN12) are frequently overexpressed in CRC, whereas claudin-8 (CLDN8) shows down-regulation in tumour tissue on RNA level. Quantification of proteins confirmed the overexpression of claudin-1 in tumour tissues, whereas changes of claudin-8 and -12 were not significantly detectable on protein level. IHC confirmed the markedly elevated expression level of claudin-1 in the majority of CRC, showing membranous and intracellular vesicular staining.

Conclusions

Differential expression of genes encoding claudins in CRC suggests that these tight junction proteins may be associated to and involved in tumorigenesis. CLDN1 is frequently up-regulated in large proportion of CRC and may represent potential target molecule for blocking studies in CRC.

Keywords

Claudin-1 Claudin-8 Tight junction Gene expression Colorectal cancer 

Notes

Acknowledgements

The presented study originated from the collaboration of the Department of General, Vascular and Thoracic Surgery, Campus Benjamin Franklin, Charité, Berlin, with metaGen, Pharmaceuticals GmbH, Berlin, Germany. We thank Prof. Dr. Med. Fischer, Institute of Pathology, Städtische Kliniken gGmbH Wilhelmshaven, Germany, for providing paraffin-embedded colorectal tissues used for validation studies and Sonja Dullat for Western blot analyses.

References

  1. 1.
    Tsukita S, Furuse M, Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2:285–293PubMedCrossRefGoogle Scholar
  2. 2.
    Madara JL (1998) Regulation of the movement of solutes across tight junctions. Annu Rev Physiol 60:143–159PubMedCrossRefGoogle Scholar
  3. 3.
    Furuse M, Itoh M, Hirase T, Nagafuchi A, Yonemura S, Tsukita S (1994) Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol 127:1617–1626PubMedCrossRefGoogle Scholar
  4. 4.
    Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539–1550PubMedCrossRefGoogle Scholar
  5. 5.
    Morita K, Furuse M, Fujimoto K, Tsukita S (1999) Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 96:511–516PubMedCrossRefGoogle Scholar
  6. 6.
    Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE (2003) Tight junction proteins. Prog Biophys Mol Biol 81:1–44PubMedCrossRefGoogle Scholar
  7. 7.
    Katoh M (2003) CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN gene family. Int J Mol Med 11:683–689PubMedGoogle Scholar
  8. 8.
    Klezovitch O, Fernandez TE, Tapscott SJ, Vasioukhin V (2004) Loss of cell polarity causes severe brain dysplasia in Lgl1 knockout mice. Genes Dev 18:559–571PubMedCrossRefGoogle Scholar
  9. 9.
    Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, Hirohashi S (2001) Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res 61:2751–2758PubMedGoogle Scholar
  10. 10.
    Weinstein RS, Merk FB, Alroy J (1976) The structure and function of intercellular junctions in cancer. Adv Cancer Res 23:23–89PubMedCrossRefGoogle Scholar
  11. 11.
    Polak-Charcon S, Shoham J, Ben-Shaul Y (1980) Tight junctions in epithelial cells of human fetal hindgut, normal colon, and colon adenocarcinoma. J Natl Cancer Inst 65:53–62PubMedGoogle Scholar
  12. 12.
    Ren J, Hamada J, Takeichi N, Fujikawa S, Kobayashi H (1990) Ultrastructural differences in junctional intercellular communication between highly and weakly metastatic clones derived from rat mammary carcinoma. Cancer Res 50:358–362PubMedGoogle Scholar
  13. 13.
    Soini Y (2005) Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 46:551–560PubMedCrossRefGoogle Scholar
  14. 14.
    Michl P, Buchholz M, Rolke M, Kunsch S, Lohr M, McClane B, Tsukita S, Leder G, Adler G, Gress TM (2001) Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121:678–684PubMedCrossRefGoogle Scholar
  15. 15.
    Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y (2000) Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res 12:469–476Google Scholar
  16. 16.
    Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115:1765–1776PubMedCrossRefGoogle Scholar
  17. 17.
    Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18:511–518PubMedCrossRefGoogle Scholar
  18. 18.
    Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA (1996) Laser capture microdissection. Science 274:998–1001PubMedCrossRefGoogle Scholar
  19. 19.
    Sugiyama Y, Sugiyama K, Hirai Y, Akiyama F, Hasumi K (2002) Microdissection is essential for gene expression profiling of clinically resected cancer tissues. Am J Clin Pathol 117:109–116PubMedCrossRefGoogle Scholar
  20. 20.
    Groene J, Mansmann U, Meister R, Staub E, Roepcke S, Heinze M, Klaman I, Brummendorf T, Hermann K, Loddenkemper C, Pilarsky C, Mann B, Adams HP, Buhr HJ, Rosenthal A (2006) Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III. Int J Cancer. DOI 10.1002/ijc.22027
  21. 21.
    Kasper G, Vogel A, Klaman I, Grone J, Petersen I, Weber B, Castanos-Velez E, Staub E, Mennerich D (2005) The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 224:93–103PubMedGoogle Scholar
  22. 22.
    Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O’Brien PM (2004) Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 10:4427–4436PubMedCrossRefGoogle Scholar
  23. 23.
    Rangel LB, Agarwal R, D’Souza T, Pizer ES, Alo PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9:2567–2575PubMedGoogle Scholar
  24. 24.
    Nichols LS, Ashfaq R, Iacobuzio-Donahue CA (2004) Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 121:226–230PubMedCrossRefGoogle Scholar
  25. 25.
    Aung PP, Mitani Y, Sanada Y, Nakayama H, Matsusaki K, Yasui W (2005) Differential expression of claudin-2 in normal human tissues and gastrointestinal carcinomas. Virchows Arch 1–7Google Scholar
  26. 26.
    Li WY, Huey CL, Yu AS (2004) Expression of claudin-7 and -8 along the mouse nephron. Am J Physiol Renal Physiol 286:F1063–F1071PubMedCrossRefGoogle Scholar
  27. 27.
    Offner S, Hekele A, Teichmann U, Weinberger S, Gross S, Kufer P, Itin C, Baeuerle PA, Kohleisen B (2005) Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol Immunother 54:431–445PubMedCrossRefGoogle Scholar
  28. 28.
    Al Moustafa AE, Alaoui-Jamali MA, Batist G, Hernandez-Perez M, Serruya C, Alpert L, Black MJ, Sladek R, Foulkes WD (2002) Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 21:2634–2640PubMedCrossRefGoogle Scholar
  29. 29.
    Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22:2021–2033PubMedCrossRefGoogle Scholar
  30. 30.
    de Oliveira SS, de Oliveira IM, De Souza W, Morgado-Diaz JA (2005) Claudins upregulation in human colorectal cancer. FEBS Lett 579:6179–6185PubMedCrossRefGoogle Scholar
  31. 31.
    Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A, Tsukita S (2002) Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156:1099–1111PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • J. Gröne
    • 1
  • B. Weber
    • 2
  • E. Staub
    • 4
  • M. Heinze
    • 1
  • I. Klaman
    • 5
  • C. Pilarsky
    • 6
  • K. Hermann
    • 7
  • E. Castanos-Velez
    • 7
  • S. Röpcke
    • 3
  • B. Mann
    • 8
  • A. Rosenthal
    • 7
  • H. J. Buhr
    • 1
  1. 1.Department of General, Vascular and Thoracic Surgery, Campus Benjamin FranklinCharité-UniversitaetsmedizinBerlinGermany
  2. 2.Immatics Biotechnology GmbHTübingenGermany
  3. 3.Department of Computational Molecular BiologyMax Planck Institute for Molecular GeneticsBerlinGermany
  4. 4.ALTANA Pharma AGKonstanzGermany
  5. 5.Institute of Pathology, Campus Benjamin FranklinCharité-UniversitaetsmedizinBerlinGermany
  6. 6.Department of Visceral, Thoracic and Vascular SurgeryUniversity Hospital DresdenDresdenGermany
  7. 7.Signature Diagnostics AGPotsdamGermany
  8. 8.Department of SurgeryAugusta-Kranken-Anstalt gGmbHBochumGermany

Personalised recommendations